| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2,804.1 | 2,534.7 |
| Profit before tax | -9.0 | 557.3 |
| Net income | -20.6 | 466.5 |
| EPS (diluted, $ a share) | $-0.14 | $3.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +10.6% |
|---|
10-Q filed with the SEC, NASDAQ: BIIB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biogen Inc.: key numbers
- Share price
- $251.65Close, Nov 16
- Market cap
- $37.2B
- Shares outstanding
- 147.82MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biogen Inc.
All →Biogen Financial Results
Biogen reported third quarter 2026 total revenue of $2.8 billion, an 11% increase year-over-year, driven by a 49% surge in its Growth Portfolio which now represents 63% of core pharmaceutical revenue. The results include the first full quarter of contribution from the acquired Apellis products and strong performance from SPINRAZA and LEQEMBI.
- Term
- Q3 2026
“Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products.”
Christopher A. Viehbacher, President and Chief Executive Officer
“With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders.”
Christopher A. Viehbacher, President and Chief Executive Officer